We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
What's new
This page lists items that we have published for the first time or updated in the last 7, 30 or 60 days. Use the filters to narrow results by audience, product type, content type or topic.
You can also stay informed by:
- subscribing to our updates to receive same-day notification emails on safety information, scheduling updates or media releases.
- checking our consultation hub.
- joining any upcoming events.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (18)
- Clinical trials (2)
- Committees and advisory bodies (5)
- Compliance and enforcement (28)
- Cosmetics (2)
- COVID-19 (2)
- Fees and payments (4)
- Import and export (13)
- Labelling and packaging (7)
- Legislation (3)
- Manufacturing (18)
- Medicinal cannabis hub (4)
- Safety monitoring and information (21)
- Scheduling (national classification system) (5)
- Shortages and supply disruptions (15)
- Sunscreens (6)
- Unique Device Identification (UDI) hub (26)
- Vaping hub (1)
- Weight loss products (3)
What's new
191 result(s) found, displaying 1 to 25
-
ConsultationWe are seeking feedback on the regulation of radiopharmaceuticals in Australia. These medicines contain small amounts of radioactive material, used to support the diagnosis and treatment of serious conditions, including cancer and cardiovascular disease.
-
ConsultationWe are seeking feedback on proposed changes to publishing information about Good Manufacturing Practice (GMP) compliance on our website.
-
ConsultationHave your say about proposals to amend the Poisons Standard. These will be considered at the next meeting of the Advisory Committee on Medicines Scheduling (ACMS), Advisory Committee on Chemicals Scheduling (ACCS), and the joint meeting of the ACMS and ACCS.
-
GuidanceThis guidance supports psychiatrists in understanding their regulatory requirements when prescribing MDMA and psilocybine from 1 July 2023.
-
PageThe EU MDR transition web publication service provides notifications to providers and consumers going through low-risk changes, as part of the transition.
-
PageThe Freedom of Information disclosure log gives access to information we've released in response to an FOI request.
-
PageUnderstand if Unique Device Identification (UDI) applies to your devices, learn how to comply and get familiar with the Australian UDI Database (AusUDID).
-
GuidanceGuidance on the process for registering new medicines with new trade names that are 'clones' of currently registered prescription medicines
-
PageRead the latest news and information related to Unique Device Identification (UDI) in Australia.
-
GuidanceGuidance explaining the post-market surveillance of listed medicines and how we undertake compliance reviews.
-
Media releasesAustralia’s health leaders are increasingly concerned about the growing availability, promotion and use of unapproved peptide products in Australia.
-
DatasetSearch approvals to import and supply medicines not in the Australian Register of Therapeutic Goods (ARTG) to address medicine shortages.
-
PageInformation about the shortages of HRT products for patients and healthcare professionals
-
GuidanceGuidance on how to advertise health services that involve therapeutic goods, including how to comply with the Act and avoid prohibited advertising.
-
GuidanceThis guidance explains the prohibitions that apply to advertising for prescription medicines.
-
PageInformation about influenza reference reagents for testing influenza vaccines and how to order them.
-
Compositional guidelinesCompositional Guideline: Lactococcus lactis subsp. lactis strain ATCC 19435 permitted for use in listed medicines.
-
Compositional guidelinesCompositional Guideline: Oxaceprol permitted for use in listed medicines.
-
Prescription medicine decision summarySlenyto has been approved for the treatment of insomnia in children and adolescents with neurogenetic disorders and/or attention-deficit hyperactivity disorder (ADHD).
-
PageLearn about the requirements for advertising therapeutic goods in specific circumstances, such as social media, and for specific types of products, like weight loss injections.
-
Media releasesWe have published new guidance on advertising restrictions for prescription medicines. This is to help individuals and businesses comply with Australia’s regulatory requirements.
-
News articlesListed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 .
-
PageLearn which therapeutic goods can and cannot be advertised to the public.
-
Meeting statementsCommunique from the 5th meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum,13 April 2026
-
PageSearch for infringement notices whereby a financial penalty may be issued in response to certain breaches of the Therapeutic Goods Act 1989 (the Act).